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Abstract
Background: Little is known about the kinetics of anti-H5 neutralizing antibodies in naturally H5N1-infected patients with
severe clinical illness or asymptomatic infection.
Methods: Using H5N1 microneutralisation (MN) and H5-pseudotype particle-based microneutralisation assays (H5pp) we
analyzed sera sequentially obtained from 11 severely ill patients diagnosed by RT-PCR (follow-up range 1–139 weeks of
disease onset) and 31 asymptomatically infected individuals detected in a sero-epidemiological study after exposure to
H5N1 virus (follow-up range: 1–2 month –11 months after exposure).
Results: Of 44 sera from 11 patients with H5N1 disease, 70% tested positive by MN (antibody titre $80) after 2 weeks and
100% were positive by 3 weeks after disease onset. The geometric mean MN titers in severely ill patients were 540 at 1–2
months and 173 at 10–12 months and thus were higher than the titers from asymptomatic individuals (149 at 1–2 months,
62.2 at 10–12 months). Fractional polynomial regression analysis demonstrated that in all severely ill patients, positive titers
persisted beyond 2 years of disease onset, while 10 of 23 sera collected 10–11 months after exposure in asymptomatically
infected individuals tested negative.
Conclusions: Our results indicate that people with asymptomatic H5N1 infection have lower H5N1 antibody titres
compared to those with severe illness and that in many asymptomatically infected patients the antibody titer decreased to
levels below the threshold of positivity within one year. These data are essential for the design and interpretation of sero-
epidemiological studies.
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Introduction
Since 1997, the highly pathogenic avian influenza A (H5N1)
virus has spread among poultry and possibly also in wild birds in
Asia, Middle-East, Europe and Africa and caused over 470 cases
of reported human diseases with more than 280 deaths [1]. The
virus evolves as it continues to circulate endemically in poultry in
many countries. Continuing occurrences of human infection
provides opportunities to H5N1 viruses to adapt to efficient
human-to-human transmission. Furthermore, the novel 2009
pandemic H1N1 virus has repeatedly been detected in pigs in
many countries including southern China (Peiris – personal
communication) and the triple-reassortant gene constellation
possessed by this virus has shown a propensity to acquire novel
viral haemagglutinin via reassortment [2]. H5N1 virus has
occasionally been documented in pigs [3]. Thus, the presence of
the pandemic virus in pigs may provide an increased risk of
reassortment between avian H5N1 viruses with the pandemic
H1N1 virus. This may allow additional opportunities for H5N1
virus adaptation to human-to-human transmission posing poten-
tially new threats to public health. Hence, it is important to
conduct sero-epidemiological studies to monitor the extent of
asymptomatic or clinically mild H5N1 illness among humans.
Such studies will also help define the risk factors for human
infections [4–10]. Serological methods are essential for the
detection of asymptomatic infections and may be helpful to
retrospectively confirm suspected cases of H5N1 disease [11]. A
significant limitation for the interpretation of serological data,
especially for sero-epidemiological studies, is the lack of informa-
tion on the kinetics of the anti-H5 neutralizing antibody response
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analyzed the characteristics of the antibody response in individuals
from Vietnam and Cambodia infected by clade 1 H5N1 virus who
experienced a spectrum of illness ranging from fatal or severe
disease to moderate illness or asymptomatic infection. Cambodia
shares are porous border for humans and poultry with South
Vietnam and during the period under study, the H5N1 viruses
isolated from southern Vietnam and Cambodia were phylogenet-
ically closely related [12].
Materials and Methods
Serum samples
Human sera were collected at the Hospital for Tropical Disease
(HTD) Ho Chi Minh City, Vietnam, from patients with severe
H5N1 virus infection confirmed by RT-PCR [13–15]. Timing of
serum collection from hospitalized patients with H5N1 disease
(N=11) between 2003 and 2005 in southern Vietnam are
summarised in table 1. Sera from Cambodia (N=1370) were
obtained from people living within 1 km radius of the households
of three H5N1 patients. None of the patients were epidemiolog-
ically linked [9,10]. All of them reported having had direct contact
with sick/dead poultry a few days to weeks before symptom onset
[9,10,16]. First blood samples were collected among village
participants ,1–2 months after the date of the patients’deaths.
We repeated blood collection for seropositive individuals 9–11
months later. These studies were approved by the Cambodian
National Ethics Committee, the Ethics and Scientific Committee
of HTD and the Oxford Tropical Research Ethics Committee
(OXTREC). A written informed consent form was obtained from
all the participants involved in the studies. Since the asymptomatic
seropositive individuals were more likely to have independently
acquired infection from poultry rather than from the index case,
the timing of their infections is imprecise. Since it is not possible to
exclude the possibility that these ‘‘asymptomatic’’ individuals may
have had a mild influenza-like illness during the period under
consideration (or that they acquired the infections months before),
we categorise H5N1 seropositives in this group as asymptomatic or
mild H5N1 virus infections. Cambodian sera were initially
screened using H5 pseudotype particles expressing the haemag-
glutinin (HA) protein of clade 1 H5N1 virus isolated in Cambodia
in 2005 [17]. Positive or indeterminate results were confirmed by
haemagglutination inhibition assay (HIA) using horse red blood
cells and ‘‘standard’’ microneutralization test (MN). For WHO, an
H5N1 infected case is defined by an haemagglutination inhibition
(HI) titer (using horse red blood cells) $1:160 and a MN titer
$1:80 [11]. However, we considered a seropositive case when the
MN titer was $1:160 with an HI test titer ,1:160 but $1:40.
H5 pseudotyped particle-based neutralization assay
H5 haemagglutinin pseudotyped lentiviral particles (H5pp) were
produced, titrated and used as described previously [17]. These
H5pp were used in place of H5N1 virus but the other steps of the
procedure followed those of the conventional microneutralization
(MN) procedure using Madin-Darby canine kidney (MDCK) cells
(American Type Culture Collection, Manassas, VA). In contrast to
conventional MN tests, the neutralization of infection in the H5pp
test was detected by measuring the reduction of end-point
chemoluminescent signal compared to controls done in absence
of sera (equivalent to 0% neutralization) and in absence of H5pp
(equivalent to 100% neutralization), respectively. Briefly, MDCK
cells (4000 cells/well) were seeded the day before infection in
white 96-well plates (Perkin Elmer) in 50 mL of complete medium.
10
5 RLU (‘‘relative’’ luminescent unit) of H5pp (quantity defined
after optimization [18]) were incubated with two-fold serial
dilution of serum (starting dilution 1:20, 60 mL/well total) for
2 h at 37uC (5% CO2 incubator). Subsequently, 100 mL of fresh
complete medium was added to the virus-antibody mix and
140 mL of the virus-antibody mix was transferred back to the cells
after the old cell medium was discarded. After 48h incubation at
37uC (5% CO2 incubator), 100 mL of Steady-Glo (Promega)
luciferase substrate was added directly. Luminescence was read 15
minutes after addition with either Micro-beta (Perkin Elmer) or
Glomax (Promega) plate readers. The neutralization titer was
defined as the reciprocal of the dilution that matches the positivity
criteria (50% neutralization) after fitting with the Hill model [19].
Microneutralization assay
One hundred tissue culture infectious dose 50 (TCID50) of A/
Vietnam/CL26/2004 (for the tests done on Vietnamese sera), A/
Cambodia/Q040547/2006 (for the tests performed on Cambodi-
an sera collected in 2006) and A/Cambodia/R0405050/2007 (for
Cambodian sera obtained in 2007) were incubated with serial two-
fold dilutions (starting from 1:10) of each serum for one hour at
room temperature prior to addition of the virus-antibody mixture
onto MDCK cells. The viruses were chosen for their close genetic
and antigenic relatedness to the strains responsible for the infection
in patients [20]. Cell monolayers were incubated for further 3–4
days and examined for cytopathic effect. Determination of
endpoint neutralizing antibody titers was performed in four wells
per dilution. The neutralizing titer was defined as the reciprocal of
the highest dilution of serum at which the infectivity of 100
TCID50 of H5N1 virus for MDCK cells was completely
neutralized in 50% of the wells. Infectivity was identified by the
presence of cytopathic effect on day 4 and the titer was calculated
by the Reed-Muench method [21].
Statistical Analysis
For the purpose of this analysis we pooled serological data
obtained by standard MN test from patients with RT-PCR
confirmed H5N1 disease in Vietnam as well as asymptomatic
infections detected by sero-epidemiological investigations in
Cambodia. We used the estimated time interval after known
exposure as a surrogate of the symptoms onset for asymptomatic
Table 1. Characteristics of individuals tested positive by
serology in Cambodia and Vietnam.
Sympto-
matic cases
Asymptomatic
or mild cases
Country of origin Vietnam Cambodia
Number of positive H5N1 cases 11 31
deaths 6 0
Median age in years (min - max) 18 (6–35) 12 (2–77)
Gender (male) 33.3% 48.4%
Median follow - up periods (in weeks) 5 28.5
Min - Max in weeks 1–139 7–51
Blood draws (n=101) 47 54
# of individuals with 1 blood draw (%) 4 (42%) 8 (26%)
# of individuals with 2 or more
blood draws (%)
7 (58%) 23 (74%)
# of individuals with 3–12
blood draws (%)
5 (45%) 0
doi:10.1371/journal.pone.0010864.t001
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were reported as geometric mean titers (GMTs). Week intervals in
which there were no observations were treated as missing values.
For H5N1 patients’ data, we used fractional polynomial regression
as a flexible parametric method for the prediction of the
relationship between immune response and time interval. We
then plotted the curve along with the confidence interval of the
GMTs. Log10 transformed GMTs were calculated for the purpose
of plotting the kinetics of the immune responses. For asymptomatic
individuals’ data, a linear model was fitted to the Cambodia data
to assess the significance of the change in titers over weeks. An F
statistic at p value ,0.05 was considered statistically significant. All
statistical analyses, graph construction, and curve-fitting as well as
95% CI were computed using STATA 9.0 (Statacorp., college
station,TX, Texas). The Two-sample Wilcoxon rank-sum (Mann-
Whitney) test was used to compare small numbers of samples. We
assessed correlation between the two assays generating the
Spearman’s correlation coefficient. We then plotted relative
differences in values using the Bland and Altman method [22]
to visualize and measure how far apart measurements between the
two assays can be.
Results
A total of 42 individuals including 11 (26%) Vietnamese H5N1-
infected patients with severe clinical disease and 31 (72%)
seropositive Cambodians with asymptomatic infection or mild
disease were analyzed. Of note, 6 of the 31 cases presented with an
MN titer $1:160 and an HI titer varying from 1:40 to 1:80. Of the
11 Vietnamese patients, 6 died. The Vietnamese H5N1-infected
patients with severe disease were older than the Cambodian
seropositive asymptomatic individuals (median 18 versus 12 years,
p=0.01). There was no difference in gender proportions between
the two groups (Table 1).
The average time of follow-up of 11 Vietnamese patients was
34.2 weeks after symptoms onset (range, 1–139 weeks; median, 5
weeks). Of these 11, seven (64%) were bled twice or more for anti-
H5N1 antibody testing at different points in time (median 6 blood
draws per patient; range, 2–11) (Tables 2 and 3). Of the 31
seropositive Cambodian individuals who were detected through
sero-epidemiological surveys, all but eight were bled twice at 1–2
months (n=31) and 10–11 months (n=23) after presumed
exposure.
Antibody kinetics using classic microneutralisation assay
In individuals who were asymptomatic or had mild disease, sera
collected 10–11 months after exposure showed a 4- to 32- fold
reduction in H5N1 neutralizing antibody titers. At this later time
point, 10 of 24 individuals (42%) had H5N1 neutralizing antibody
titers lower than 1:80 (ranging from 1:20 to 1:40). These ten
individuals also had the lowest initial H5N1 neutralizing antibody
titers (1:80) (figure 1). Of the six severely ill patients whose blood
was collected during 1–7 days of fever onset (week 1), all tested
negative (GMT =1:13.2). Of the 10 blood samples collected
among six patients during week 2, seven (70%; 95% CI 34.8–
93.3%) tested positive with GMT at 1:215. Finally, of the five
patients tested within week 3, four had antibody titers $1:80
(GMT =1:867). Of the four severely ill patients who were bled for
serological testing beyond one year of disease onset (range 1–2.6
years), all tested positive with antibody titers of .1:80. Of these
four, the maximum values of their antibody titers were observed
between weeks 2 and 12 of symptom onset (range 1:1,995–
1:7,943).
Antibody kinetics using H5 pseudotyped particle-based
neutralization assay
Antibody kinetics measured by H5pp were similar to that from
MN assay (Figures 1 & 2). There was good correlation between
titers measured by the two methods (Spearman’s correlation
coefficient of 0.79, p,0.001). Moreover the Bland Altman plot
showed that on average H5pp titers were higher by 31.9% (95%
CI 17.1%–46.7%) with 95% limits of agreement between
2115.6% and +179.5% (units for limits of agreement were
expressed in relative differences = H5pp titers – MN titers/(H5pp
titers +MN titers/2)) (Figure 3). For instance a +179.5% relative
difference between the two assays means that H5pp titers were at
,2 fold-dilution higher than that of MN.
Regression model analysis
The fractional polynomial regression model for symptomatic
individuals predicted a rise of neutralizing antibody titers $1:80 at
week 2 and a peak at week 5 or 6 for the 2 assays (Figure 2).
Interestingly, the model also predicted positive serology among
symptomatic cases using both assays beyond 1 or 2 years after
symptoms onset or exposure to H5N1 virus. GMT from sera
collected in symptomatic cases (n=4) at 1–2 months after the
Table 2. Time of seroconversion and mean antibodies titers measured 3 weeks after onset of disease or presumed exposure.
Symptomatic cases
Asymptomatic or mild
cases
MN* H5pp* MN* H5pp*
Titers $1:80 among
Blood samples in Week 1 of fever onset (n=6)** 0 (0%) 1 (17%)
Blood samples in Week 2 of fever onset (n=10)** 7 (70%) 5 (50%)
Blood samples in Week 3 of fever onset (n=5)** 4 (80%) 4 (80%)
Titers measured after week 3 of fever onset or presumed exposure
Geometric mean titers 372 817 102 137
Min 80 80 80 80
Max 7,943 10,169 2,560 15,375
*MN= standard microneutralization test; *H5pp= Pseudotyped H5 particles-based microneutralisation test.
**Only available among H5N1-infected patients.
doi:10.1371/journal.pone.0010864.t002
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H5N1 virus infection, 2003/2004.
# sera
Timing of collection
(days post onset)
Antibody titers measured by
MN* and H5pp* Outcome Patient identifier in references
[26] [12]
Cl 1 9 138–5 survived Patient 5 Patient 6
12 135–57
13 100–208
21 501–850
31 1259–1055
77 1995–2488
203 537–1174
Cl 4 6 1–1 died Patient 7 n/a
10 50–7
13 32–40
17 1–29
Cl 17 5 45–6 died Patient 8 n/a
Cl 26 6 1–12 survived Patient 10 Patient 7
18 5012–10169
28 1413–2323
68 537–2465
188 316–624
420 224–995
421 224–219
551 224–409
Cl 36 12 891–753 survived n/a Patient 8
15 7943–5475
25 1259–4978
33 759–3873
45 631–565
59 166–473
95 398–1892
246 251–461
400 112–851
760 224–282
773 72–201
Cl 100 19 112–863 died n/a Patient 3
Cl 101 6 17–54 died n/a n/a
Cl 107 7 40–165 died n/a Patient 4
10 158–199
11 63–255
Cl 112 9 122–226 died n/a n/a
Cl 114 10 200–34 survived n/a n/a
80 126–527
Cl 115 5 32–47 survived n/a Patient 5
116 158–133
268 126–262
416 126–650
429 224–821
444 158–331
*MN= standard microneutralization test; *H5pp= pseudotyped H5 particles-based microneutralization test.
doi:10.1371/journal.pone.0010864.t003
Kinetics of Anti-H5 Antibodies
PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10864symptoms onset tend to be higher than that of asymptomatic cases
(n=31) after 1–2 months of exposure (GMT 540 versus 149;
p=0.084 by MN and GMT 1,266 vs. 228; p=0.017 by H5pp). In
addition, these differences in GMT significantly increased between
symptomatic cases (4 patients whose sera were collected at 12–14
months of symptoms onset) and 23 asymptomatic individuals bled
at 10–11 months after exposure (GMT 173.0 versus 62.2,
p=0.004 by MN and GMT 420 versus 71, p=0.010 by H5pp).
Discussion
This study analysed the kinetics of the anti-H5N1 virus
neutralizing antibody response in naturally infected patients with
symptomatic and asymptomatic or mild infection. Overall, the
titers of antibodies measured by both MN and H5pp assays were
generally higher in hospitalized patients with severe H5N1 disease
than in subclinically infected individuals. Serological evidence of
infection (titer $1:80) was still detectable by both assays in severe
H5N1 cases for periods up to the limit of follow-up at 2 years,
contrasting with a shorter longevity of detectable antibodies in
subclinical cases of whom a substantial proportion declined to
titers below 1:80 within 10 months after presumed exposure.
Higher initial titers during the acute phase, rather than differences
in decay rate, could explain persistence of significant titers over a
longer period of time among sick patients. Indeed, the slopes of the
decay of titers were not significantly different between the two
groups of cases when using linear regression modelling (data not
shown). These findings suggest that conducting serosurveys could
still be relevant within several months of the exposure, and that the
level of antibody titers in a human population combined with
information about the timing of poultry outbreaks and about
H5N1 morbidity and mortality among humans could serve as a
tool to accurately measure and monitor the extent of transmission
as well as the risk factors for transmission and disease in a given
area or premise (i.e. markets).
Among patients hospitalized in Vietnam for clinically
apparent H5N1 infection, we observed that no neutralizing
antibodies were detected during the first week after the onset of
the disease while an antibody titer $1:80 was detectable in 70%
by day 14 and in 80% of patients by day 21. It cannot be
excluded that the patient that did not test positive by day 17
would never seroconvert, as previously described in other
patients infected with H5N1- or other influenza viruses [23,24].
We found that only two-thirds of patients between day 7–14 had
serological evidence of infection. This suggests the conduct of
serological testing among patients after 2 weeks of disease onset
or exposure to the virus, which is consistent with the WHO
recommendations.
Figure 1. H5 neutralizing antibody titers by H5pp (1a) and MN (1b) tests in 31 asymptomatic/mild individuals. Orange lines: Fig. 1a:
Linear regression line (slope of –0.06, p value =0.172). Fig1b: Linear regression line (slope of –0.31, p value =0.024). Cross points: Seropositive cases’
neutralizing antibody titers at Weeks 7, 9, 48 and 51 after exposure (n=54). Green line: Threshold titer at 80.
doi:10.1371/journal.pone.0010864.g001
Figure 2. H5 neutralizing antibody titers by H5pp (2a) and MN (2b) tests in 11 severely ill H5N1 patients. Orange dots: Geometric
means of titers by week (n=47). Blue lines: Fractional polynomial regression line. Grey zones: 95% confidence interval around fractional polynomial
regression line. Green line: Threshold titer at 80.
doi:10.1371/journal.pone.0010864.g002
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antibody titer in clinically ill patients who develop a specific
immune response should be higher than 1:80 by day 14 after onset
of symptoms and peaks 2 to 10 weeks after symptom onset. The
curve suggests that during the peak, the average expected titer
should be between 1:320 and 1:640. Interestingly, even 2 years
after H5N1 disease, serology should still be positive in most of
these severe human cases. To our knowledge, the kinetic data were
only documented in 8 severely ill Thai patients naturally infected
by H5N1 virus [24]. Our results observed in additional
symptomatic patients from Vietnam were similar and consistent
with that of Thailand.
For the patients with subclinical H5N1 infection, we observe a
titer approximately 3 times lower at the time of recruitment by
comparison with patients who developed severe symptoms. The
average titer (1:150) at the time of blood draw (1–2 months after
exposure) is just two fold dilution higher than the cut-off value,
hence the importance of using neutralization-based methods,
which seems to be more sensitive than HI test, and choosing the
most appropriate virus for these tests [25]. After approximately
40–45 weeks, the titres in 42% of the subclinical cases had already
declined to levels below 1:80, especially in those who had an initial
titer close to the cut-off value. On the basis of the current criteria
of serological evidence of H5 infection, about half of subclinically
H5N1-infected thus will not be identified if tested one year after
exposure. Therefore, seroepidemiological studies should be
implemented very early (but not before 3 weeks) after the
supposed date of exposure to the H5N1 virus. As a result, the
dates of exposure are indispensible for interpreting population-
based seroepidemiological data.
The interpretation of our findings is subject to several
limitations. The MN tests on the asymptomatic (Cambodian sera)
and symptomatic (Vietnamese) sera were done using identical
protocols but in two laboratories using different clade 1 H5N1
viruses isolated in Cambodia and Vietnam, respectively. These
limitations and the inter-laboratory variations have been high-
lighted in a recent study [25] but cannot easily be overcome,
especially since there are strict restrictions in the movement of
clinical specimens and virus isolates across national borders. On
the other hand, each laboratory used for its MN tests the viruses
autologous to the local infecting virus which would likely increase
the sensitivity. Furthermore, these clade 1 viruses in Vietnam and
Cambodia were antigenically and phylogenically very closely
related to each other. However, to ensure comparability, we
retested all sera using the H5pp method at the two laboratories.
This assay used the same virus pseudo-particles and the same
reagents and was therefore easier to standardize [18]. Given the
good agreement and correlation between the standard MN and
the H5pp-based microneutralisation test in both sites, we believe
our findings accurately describe the overall patterns of the kinetics
of H5N1 antibodies. The good correlation of the results between
MN and H5pp also provides independent validation for the use of
the H5pp assay as a surrogate for MN tests and one that can be
done without the need for BSL-3 containment of highly
pathogenic viruses. Secondly, although we managed to follow-up
many infected individuals, broad variations exist with regard to the
number of serum samples collected per person and the period of
follow-up. Therefore many of our inferences between time and
titer levels, particularly during the early rise of antibody response,
were based on small numbers of data-points at each week time
Figure 3. Comparison of H5pp and MN tests by Bland & Altman method. On the x axis, the means of the H5 titers observed with the two
methods are shown for individual samples. On the y axis, the difference between the methods divided by the means of the titers presented in
percent. The limits of agreements are depicted. A total of 101 sera were included in the analysis. Bland and Altman plot, N =101. Bias: 31.9% [95%
Confidence Interval =+17.1% to +46.7%]. Limits of agreement =2115.6% and +179.5%.
doi:10.1371/journal.pone.0010864.g003
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surveys with paired samples collected at the early stage of the
suspected exposure and two to three weeks later so that the period
of infection is more precisely defined.
Conclusion
There is little data available on the natural history and kinetics
of the antibody response to influenza H5N1 infection over time,
crucial information required to inform the design of seroepidemi-
ological studies. We have demonstrated a good correlation in the
profiles of antibody response of the H5pp and MN titres hence
confirming the validity of the H5pp test as a screening test in
seroepidemiological studies of H5N1 infection. Our data provide
important novel insights into these dynamics of the serological
responses in patients with the full spectrum of clinical disease from
severe through mild to asymptomatic H5N1 infection. Whilst
community based seroepidemiology testing after one year may
pick up people with clinically apparent infection it may fail to show
the true extent of the community exposure to H5N1 as the
antibody response apparently wans faster in those individuals who
were mildly symptomatic or asymptomatic. Hence delayed
community seroprevalence studies for H5N1 may underestimate
the true burden of human infection.
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